Literature DB >> 19225402

Nonalcoholic fatty liver disease among HIV-infected persons.

Nancy Crum-Cianflone1, Angelica Dilay, Gary Collins, Dean Asher, Richard Campin, Sheila Medina, Zach Goodman, Robin Parker, Alan Lifson, Thomas Capozza, Mary Bavaro, Braden Hale, Charles Hames.   

Abstract

OBJECTIVE: To describe the prevalence and factors associated with nonalcoholic fatty liver disease (NAFLD) among HIV-infected persons not infected with hepatitis C virus (HCV).
DESIGN: : A cross-sectional study among HIV-infected patients in a large HIV clinic.
METHODS: NAFLD was defined as steatosis among patients without viral hepatitis (B or C) coinfection or excessive alcohol use. The prevalence of NAFLD was identified by ultrasound examination evaluated by 2 radiologists blinded to the clinic information; liver biopsies were performed on a subset of the study population. Factors associated with NAFLD were evaluated by proportional odds logistic regression models.
RESULTS: Sixty-seven of 216 patients (31%) had NAFLD based on ultrasound evaluation. Among those with NAFLD, steatosis was graded as mild in 60%, moderate in 28%, and severe/marked in 12%. Factors associated with the degree of steatosis on ultrasound examination in the multivariate model included increased waist circumference [odds ratio (OR) 2.1 per 10 cm, P < 0.001], elevated triglyceride levels (OR 1.2 per 100 mg/dL, P = 0.03), and lower high-density lipoprotein levels (OR 0.7, per 10 mg/dL, P = 0.03). African Americans were less likely to have NAFLD compared with whites (14% vs. 35%), although this did not reach statistical significance (OR 0.4, P = 0.08). Similar associations were noted for the subset of patients diagnosed by liver biopsy. CD4 cell count, HIV viral load, duration of HIV infection, and antiretroviral medications were not independent risk factors associated with NAFLD after adjustment for dyslipidemia or waist circumference.
CONCLUSIONS: NAFLD was common among this cohort of HIV-infected HCV-seronegative patients. NAFLD was associated with a greater waist circumference, low high-density lipoprotein, and high triglyceride levels. Antiretroviral medications were not associated with NAFLD; prospective studies are needed to confirm this finding.

Entities:  

Mesh:

Year:  2009        PMID: 19225402      PMCID: PMC2782375          DOI: 10.1097/QAI.0b013e318198a88a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  52 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Hepatic steatosis: a frequent non-specific finding in HIV-infected children.

Authors:  M Albisetti; C P Braegger; T Stallmach; U V Willi; D Nadal
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

3.  The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.

Authors:  A J Wigg; I C Roberts-Thomson; R B Dymock; P J McCarthy; R H Grose; A G Cummins
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  A sonographic-pathological correlation of liver biopsies in patients with the acquired immune deficiency syndrome (AIDS).

Authors:  T J Beale; C W Wetton; M E Crofton
Journal:  Clin Radiol       Date:  1995-11       Impact factor: 2.350

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.

Authors:  T M Riddle; D G Kuhel; L A Woollett; C J Fichtenbaum; D Y Hui
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

7.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

8.  Hepatomegaly with severe steatosis in HIV-seropositive patients.

Authors:  J P Freiman; K E Helfert; M R Hamrell; D S Stein
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

9.  Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease.

Authors:  A E Joseph; S H Saverymuttu; S al-Sam; M G Cook; J D Maxwell
Journal:  Clin Radiol       Date:  1991-01       Impact factor: 2.350

10.  Hepatic and biliary tract abnormalities in patients with AIDS. Sonographic-pathologic correlation.

Authors:  K Grumbach; B G Coleman; A A Gal; P H Arger; M C Mintz; R L Arenson; L Aquino
Journal:  J Ultrasound Med       Date:  1989-05       Impact factor: 2.153

View more
  63 in total

Review 1.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

2.  Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.

Authors:  N Agarwal; A Balasubramanyam
Journal:  Adipocyte       Date:  2014-10-30       Impact factor: 4.534

Review 3.  Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Authors:  Paul Kelly; Haroon Saloojee; Jennifer Y Chen; Raymond T Chung
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.

Authors:  Thomas D Schiano; Alison Uriel; Douglas T Dieterich; M Isabel Fiel
Journal:  Virchows Arch       Date:  2010-11-06       Impact factor: 4.064

Review 5.  Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

Authors:  Bassem Matta; Tzu-Hao Lee; Keyur Patel
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

6.  Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Authors:  Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

7.  Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.

Authors:  Jennifer C Price; Jennifer L Dodge; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

8.  Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

Authors:  David R Bakal; Lara E Coelho; Paula M Luz; Jesse L Clark; Raquel B De Boni; Sandra W Cardoso; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

9.  Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.

Authors:  V Borghi; L Bisi; L Manzini; A Cossarizza; C Mussini
Journal:  Infection       Date:  2012-12-09       Impact factor: 3.553

10.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.